Hepatic Tumor - Pipeline Insight, 2025

DelveInsight’s, “Hepatic Tumor - Pipeline Insight, 2025,”report provides comprehensive insights about 75+ companies and 75+ pipeline drugs in Hepatic Tumor pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Hepatic Tumor Understanding

Hepatic Tumor: Overview

Hepatic tumors, also known as liver tumors, encompass a broad spectrum of growths that can develop within the liver. These tumors can be benign or malignant and may originate from hepatocytes, the primary cell type in the liver, or from other cell types within the liver. The most common types of hepatic tumors include hepatocellular carcinoma (HCC), which arises from hepatocytes, and cholangiocarcinoma, which originates from the bile ducts within the liver. Other less common types include hepatic adenomas, focal nodular hyperplasia, and hemangiomas.

The causes of hepatic tumors are multifactorial and may include chronic liver diseases such as hepatitis B or C infection, alcoholic liver disease, non-alcoholic fatty liver disease (NAFLD), and certain genetic conditions. Environmental factors such as exposure to aflatoxins, a type of toxin produced by molds commonly found in grains and nuts, may also increase the risk of developing hepatic tumors. Additionally, lifestyle factors such as obesity, smoking, and excessive alcohol consumption are associated with an increased risk of liver cancer.

Symptoms of hepatic tumors can vary depending on the type of tumor and its size. Some common symptoms include abdominal pain or discomfort, unexplained weight loss, loss of appetite, nausea, jaundice (yellowing of the skin and eyes), and an enlarged liver. Diagnosis typically involves imaging studies such as ultrasound, CT scans, or MRI scans, as well as blood tests to assess liver function and tumor markers. Treatment options may include surgery, chemotherapy, radiation therapy, targeted therapy, and liver transplantation, depending on the type and stage of the tumor. Early detection and intervention are crucial for improving outcomes and prognosis in patients with hepatic tumors.

""Hepatic Tumor - Pipeline Insight, 2025"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Hepatic Tumor pipeline landscape is provided which includes the disease overview and Hepatic Tumor treatment guidelines. The assessment part of the report embraces, in depth Hepatic Tumor commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Hepatic Tumor collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Hepatic Tumor R&D. The therapies under development are focused on novel approaches to treat/improve Hepatic Tumor.

Hepatic Tumor Emerging Drugs Chapters

This segment of the Hepatic Tumor report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Hepatic Tumor Emerging Drugs

• Namodenoson: Can Fite Biopharma

Namodenoson is a small molecule A3 adenosine receptor (A3AR) agonist. It is an oral drug currently being developed for the treatment of oncology diseases including advanced liver cancer(hepatocellular carcinoma), pancreatic cancer and metabolic associated steatohepatitis (MASH). Currently it is in Phase III stage of clinical trial evaluation to treat Hepatocellular Carcinoma.

• MTL CEBPA : MiNA Therapeutics

MTL-CEBPA is a novel medicine being developed as a combination therapy in cancer. MTL-CEBPA is designed to reduce immune suppression of myeloid cells by restoring C/EBP-α protein to normal levels using the RNA Activation mechanism. The drug candidate uses the RNA interference mechanism of action. Currently being evaluated in the Phase II studies for the treatment of Hepatic Tumor.

• Amivantamab: Janssen Research & Development, LLC

Amivantamab is a fully-human EGFR-MET bispecific antibody with immune cell-directing activity that targets tumors with activating and resistance EGFR mutations and MET mutations and amplifications. The drug is based on antibody-dependent cell cytotoxicity mechanism of action. The drug is in Phase II stage of clinical trials for the treatment of Hepatic Tumor.

• Fostroxacitabine bralpamide: Medivir AB

Fostroxacitabine bralpamide is a small molecule a type of smart chemotherapy that delivers the cell-killing compound selectively to the tumor while minimizing the harmful effect on normal cells. being developed by Medivir AB. It works as Nucleotide DNA polymerase inhibitor. The drug candidate is administered through oral route. Currently the drug is being evaluated in Phase I/II for the treatment of Hepatic Tumor.

• ETN101: Etnova Therapeutics Corp.

ETN101 is a synthetic drug candidate designed to be a best-in-class anticancer agent targeting hepatocellular carcinoma. It is being developed with the aim of preoccupying the market for both first-line and follow-up treatments of hepatocellular carcinoma with its high rate of complete remission and safety. It inhibits protein activity using FLT3/KIT/VEGFR2/PDGFRB tyrosine kinase inhibitors and its downstream signaling pathways: PI3K/AKT and RAS-MAPK, working as multiple tyrosine kinase inhibitors (mTKI). The drug is in Phase I stage of clinical trials for the treatment of Hepatic Tumor.

Further product details are provided in the report……..

Hepatic Tumor Therapeutic Assessment

This segment of the report provides insights about the different Hepatic Tumor drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Hepatic Tumor

There are approx. 75+ key companies which are developing the therapies for Hepatic Tumor. The companies which have their Hepatic Tumor drug candidates in the most advanced stage, i.e. phase III include, Can Fite Biopharma.

• Phases

Delve Insight’s report covers around 75+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Hepatic Tumor pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Parenteral
• intravenous
• Subcutaneous
• Topical.
• Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Hepatic Tumor: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III II, I, preclinical and discovery stage. It also analyses Hepatic Tumor therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Hepatic Tumor drugs.

Hepatic Tumor Report Insights

• Hepatic Tumor Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Hepatic Tumor Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Hepatic Tumor drugs?
• How many Hepatic Tumor drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Hepatic Tumor?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Hepatic Tumor therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Hepatic Tumor and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Can Fite Biopharma
• MiNA Therapeutics
• Medivir AB
• Janssen Research & Development, LLC
• Etnova Therapeutics Corp.
• SillaJen Biotherapeutics
• Akeso Biopharma
• Shanghai Junshi Biosciences
• Genmab/Janssen Biotech
• Bio-Thera Solutions
• Ocuphire Pharma
• Surface Oncology
• Genoscience
• Onyx Pharmaceuticals
• Qurient Co., Ltd.
• Kowa Company, Ltd.
• Eureka Therapeutics Inc.

Key Products

• Namodenoson
• MTL CEBPA
• Fostroxacitabine bralpamide
• Amivantamab
• ETN101
• Pexastimogene devacirepvec
• Cadonilimab
• Toripalimab
• Amivantamab
• Bevacizumab biosimilar
• APX3330
• SRF388
• GNS561
• PD-0332991
• Q702
• NIK-333
• ET14020